Patients meeting the composite endpoint of MACE (major adverse CV events, defined as CV death, heart failure, stroke, myocardial infarction, or repeated revascularization) had a significantly higher hs-CRP (p = 0.033). The gene discussed is CRP; the disease is heart failure.